Is expression of rat breast matrix components influenced by estrogen, progestins and tibolone?

Cunha, E P; Pompei, Luciano de Melo; Theodoro, Therésè Rachell; Steiner, Marcelo Luis; Silva, V. F.; Silveira, Elaine; Mader, Ana Maria Amaral Antonio; Pinhal, Maria Aparecida da Silva; Fernandes, César Eduardo

doi:10.3109/13697137.2015.1007122

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results points to that miR-22 can be a possible regulatory mechanism between perlecan and the ER status of the tumour. Pompei et al have shown that oestrogen pharmacologically administered to castrated rats led to an increased level of perlecan in the carotid walls [42], and in rat mammary tiss u e , e s t r a d i o l b e n z o a t e i n c o m b i n a t i o n s w i t h medroxyprogesterone acetate, induced perlecan production and increased breast tissue proliferation [43]. These reports further support that oestrogen and perlecan are connected to each other.…”

Section: Discussionmentioning

confidence: 99%

Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling

Jansson

Billing

Herdenberg

et al. 2020

J Mammary Gland Biol Neoplasia

View full text Add to dashboard Cite

Localised breast cancer can be cured by surgery and adjuvant treatments, but mortality remains high as some tumours metastasize early. Perlecan is a basement membrane (BM) protein involved in tumour development and progression. Here, mRNA and protein expression of perlecan, and mRNA expression of matrix degrading enzymes were studied in normal breast and invasive breast cancer, and correlated to prognostic risk factors, in particular oestrogen status. Moreover, plasma levels of perlecan were measured in patients with breast cancer and compared with controls. mRNA data was extracted from the Cancer Genome Atlas database. Perlecan protein expression was visualized using immunofluorescence and plasma levels measured by ELISA assay. Perlecan mRNA levels were twice as high in normal breast compared with breast cancer tissue. A strong correlation was found between mRNA expression of perlecan and several matrix-degrading enzymes in oestrogen receptor positive (ER+) tumours. Perlecan protein was localized to both epithelial and vascular BMs, but absent in the stroma in normal breast. In breast cancer, the expression of perlecan in epithelial BM was fragmented or completely lost, with a marked upregulation of perlecan expression in the stroma. Significantly higher levels of perlecan were found in plasma of ER+ patients when compared with ER-patients. This study shows that perlecan expression and degradation in breast cancer may be linked to the ER status of the tumour.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling

Jansson

Billing

Herdenberg

et al. 2020

J Mammary Gland Biol Neoplasia

View full text Add to dashboard Cite

show abstract

Is expression of rat breast matrix components influenced by estrogen, progestins and tibolone?

Abstract: There was no difference in the effects of combinations of estradiol and different progestogens on extracellular matrix components, and breast cell proliferation was associated with increases in perlecan and MMP-9.

Cited by 1 publication

References 16 publications

Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling

Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling

Contact Info

Product

Resources

About